Formulation, characterization and pharmacological evaluation of anti-inflammatory polyphyto matrix tablet as a novel drug delivery system
Main Article Content
Abstract
Objective: To deal with the formulation, characterization and pharmacological evaluation of anti-inflammatory polyphyto matrix tablet containing Carica papaya, Vitex negundo, Moringa oleifera and Boswellia serrata used as a novel drug delivery system. An attempt has been made to develop polyphyto matrix tablets by using HPMC and ethyl cellulose. Methods: Pharmacological screening of polyphyto matrix tablet was evaluated by using the carrageenan-induced paw edema rat model and the study carried out by using various doses (100, 200 and 300 mg/kg body weight) of three different polyphyto matrix formulations. Diclofenac sodium was used as a standard drug, due to its considerable report on antiinflammatory importance. Data were expressed by mean±SD; statistical analysis was performed by using ANOVA and p less than 0.05 considered as statistically significant. Results: Physical and chemical evaluation parameters of polyphyto matrix formulation exhibits potent and dose-dependent anti-inflammatory activity in all the tested animal groups. Formulation F1 significantly (p less than 0.05) suppresses the inflammation in the rat paw and found to be preeminent and stable in comparison with standard and other two (F2 and F3) formulations. Conclusion: Study reveals that the polyphyto matrix formulation could be useful as either an alternative or a complementary therapy in the management of all types of inflammation. It may be due to presence of terpenoids, alkaloids, glycosides and other phytochemical in herbs.
Article Details
How to Cite
1.
Maurya H, Kumar T. Formulation, characterization and pharmacological evaluation of anti-inflammatory polyphyto matrix tablet as a novel drug delivery system. IJPBR [Internet]. 30Sep.2016 [cited 17Nov.2024];4(03):50-7. Available from: https://ijpbr.in/index.php/IJPBR/article/view/914
Section
Table of Content
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.